<PAGE> 1
For Immediate Release
For Further Information Contact:
Teresa Bongartz, 301-608-9292
Email [email protected]
UNITED THERAPEUTICS CORPORATION DISCONTINUES UT-77 PROJECT
IN PHASE II OF DEVELOPMENT
Silver Spring, MD, June 27, 2000: United Therapeutics Corporation (NASDAQ: UTHR)
announced today that it discontinued its UT-77 drug development project based on
preclinical results and Phase II testing. UT-77 is a serine elastase inhibitor
inlicensed in 1998 from Cortech, Inc. for development in chronic obstructive
pulmonary disease. United Therapeutics has thus terminated its exclusive license
with Cortech.
United Therapeutics is a pharmaceutical company with Phase III drug development
programs in pulmonary hypertension, peripheral vascular disease and
osteoarthritis, as well as preclinical activities in cardiovascular, respiratory
and infectious diseases.
* * * * * *
